Presentation by Ferenc Emil Mozes, Postdoctoral Research Assistant, OCMR at the University of Oxford, UK

Systematic evaluation of non-invasive imaging and serum-based tests for detecting NAFLD

Share this article:

Explore the potential of new non-invasive imaging- and serum-based markers

The rising prevalence of NAFLD and NASH is leading to an increased burden on healthcare providers, as well as contributing to increased risk of developing end-stage liver disease or hepatocellular carcinoma. Whereas liver biopsy is still the gold standard for diagnosing NAFLD, in this presentation Ferenc Emil Mozes explores the potential of the new non-invasive imaging- and serum-based markers that have emerged in recent years.